CLRPF.US Clarity Pharmaceuticals Ltd

Healthcare Biotechnology USA Stocks
1.28 USD
Close of Nov 13, 2026
1.00 2.89
Market cap
USD 478M
P/E
-
P/B
4.09x
ROE
-57.6%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Jun 2026.

Is CLRPF.US undervalued?

Graham number

The Graham number of Clarity Pharmaceuticals Ltd cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Clarity Pharmaceuticals Ltd fundamental analysis

No fundamental analysis for Clarity Pharmaceuticals Ltd yet.

Clarity Pharmaceuticals Ltd stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Clarity Pharmaceuticals Ltd

Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development of radiopharmaceutical products for oncology in Australia and the United States. The company's lead product is SAR-bisPSMA, a theranostic radiopharmaceutical for the treatment of Prostate Specific Membrane Antigen (PSMA) cancer. It also develops SAR-Bombesin, a pan cancer theranostic radiopharmaceutical to treat prostate, breast, ovarian, urinary, small cell lung ca…

Full company profile